相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease
Usha Panchapakesan et al.
CLINICAL SCIENCE (2013)
A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) inpatients with type 2 diabetes
S. J. Yang et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
E. J. Rhee et al.
DIABETES OBESITY & METABOLISM (2013)
Ulinastatin inhibits unilateral ureteral obstruction-induced renal interstitial fibrosis in rats via transforming growth factor β (TGF-β)/Smad signalling pathways
Xiao-hua Ning et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2013)
Chronic unilateral ureteral obstruction in the neonatal mouse delays maturation of both kidneys and leads to late formation of atubular glomeruli
Michael S. Forbes et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2013)
Cardiovascular protective properties of incretin-based therapies in type 2 diabetes
Suat Simsek et al.
CURRENT OPINION IN LIPIDOLOGY (2012)
Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes Role of dipeptidyl peptidase-IV inhibition
Maria Rosaria Rizzo et al.
DIABETES CARE (2012)
High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV
C. Marchetti et al.
DIABETOLOGIA (2012)
Renal and Cardiac Effects of DPP-4 Inhibitors - from Preclinical Development to Clinical Research
Berthold Hocher et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2012)
DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury
Lorenzo L. F. Glorie et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2012)
Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats
Wei Jing Liu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)
Cristina Mega et al.
EXPERIMENTAL DIABETES RESEARCH (2011)
Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy
Lyubov Chaykovska et al.
PLOS ONE (2011)
A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes
E. J. Rhee et al.
DIABETES OBESITY & METABOLISM (2010)
Expanding the Dipeptidyl Peptidase 4-Regulated Peptidome via an Optimized Peptidomics Platform
Arthur D. Tinoco et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
HMGB1 Contributes to Kidney Ischemia Reperfusion Injury
Huiling Wu et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy
Sally A. Penfold et al.
KIDNEY INTERNATIONAL (2010)
Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers
Kyoung Soo Lim et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Pharmacokinetics, Pharmacodynamics, and Tolerability of the Dipeptidyl Peptidase IV Inhibitor LC15-0444 in Healthy Korean Men: A Dose-Block-Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose, Phase I Study
Kyoung Soo Lim et al.
CLINICAL THERAPEUTICS (2008)
Possible involvement of SDF-1α/CXCR4-DPPIV axis in TGF-β1-induced enhancement of migratory potential in human peritoneal mesothelial cells
Hiroaki Kajiyama et al.
CELL AND TISSUE RESEARCH (2007)
Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction
N. D. Vaziri et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy
RGB Bonegio et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
High-mobility group box 1 protein (HMGB): Nuclear weapon in the immune arsenal
MT Lotze et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Circulating CD26 is negatively associated with inflammation in human and experimental arthritis
N Busso et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
D Kim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Cytokines and glucocorticoids differentially regulate APN/CD13 and DPPIV/CD26 enzyme activities in cultured human dermal fibroblasts
JM Sorrell et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2003)
The multifunctional or moonlighting protein CD26/DPPIV
E Boonacker et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2003)
Involvement of dipeptidyl peptidase IV in immune complex-mediated glomerulonephritis
T Shinosaki et al.
LABORATORY INVESTIGATION (2002)
Moonlighting functions of polypeptide elongation factor 1: From actin bundling to zinc finger protein R1-associated nuclear localization
S Ejiri
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY (2002)
分享论文
